RE:RE:RE:RE:RE:ASCO Presentation - 28% CR at 450 Days
Eoganacht wrote: Two months ago Ferring Pharmaceuticals received FDA approval for Adstiladrin for high-risk, BCG-unresponsive NMIBC based on a CR rate at 12 months of 23.5%. Today Theralase announced to a symposium of genitourinary oncologists a CR rate at 15 months of 28% for the same indication. TLD1433 pdt has higher efficacy, a more enduring response, and better results are likely on the way.
On May 1 Theralase will be presenting updated (and very likely better) results to the 20,000 member AUA, (the American Urology Association).
Up to now TLD1433 pdt has not been part of the public conversation among urologists with respect to NMIBC options. I think that's about to change. Also, IMHO, FDA approval is on it's way.
To add....viral-vector gene therapies are certainly not harmless & they come with a hefty monetary & physical price....in the Adstiladrin trial, 34% of patients had interruptions in their treatments due to adverse reactions. It is also a drug that should not be taken by those who are immunosuppressed.
I believe their reported 23.5% durable response (DR) does reflect the percentage of patients who maintained a CR for at least 12 months. Nonetheless, it is significantly below our current DR, which as you said, should improve based on our data trends using the optimized protocol.
Excited for our day at the upcoming AUA meeting...I consider it a day of enlightenment for many uro-oncologists who still have no clue there's a better/patient-friendly option on the horizon...all imo. Good luck.